Page 2 - Zydus Lifesciences Ltd News

Stocks to Watch today, Nov 4: Bharti Airtel, Titan, Hero MotoCorp, Cipla

Stocks to Watch today, November 4, 2025: From Bharti Airtel, Hero MotoCorp, Titan Company, and Power Grid, here is a list of stocks that will be in focus today

Stocks to Watch today: Coal India, L&T, Wipro, Bharti Airtel, Ola Electric

Stocks to Watch Today, October 30, 2025: Wipro, L&T, Coal India, United Breweries, Ola Electric, ITC, Swiggy, Mankind Pharma, and Dr Reddy's Labs are among the top stocks to watch today

Stocks to Watch today, Oct 7: LTIMindtree, Bank of India, HCL Tech, OIL

Stocks to Watch today, October 7, 2025: From Bank of India, HCL Tech to Eternal, here is a list of stocks that will be in focus

Tariff uncertainties may spur rise in third-party pharma manufacturing

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Stocks to watch today, Sep 8: SpiceJet, TaMo, M&M, Vedanta, BHEL, HFCL

Stocks to watch today, September 8, 2025 | Aurobindo Pharma: USFDA issued 8 procedural observations after inspecting Telangana Unit-XII.

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Zydus Lifesciences' Q1 dose lifts vitals, but outlook stays fragile

April-June Qtr beat offsets some caution, yet US headwinds cap upside

Zydus Lifesciences Q1 PAT up 5.9% on strong India, int'l formulations biz

The growth was driven by strong performances in the company's domestic and international formulations segments, even as its consumer wellness and US businesses saw muted growth

Zydus Lifesciences Q1 results: Profit up 3% at ₹1466.8 cr, revenue rises 6%

Revenue from operations climbed 5.9 per cent Y-o-Y to ₹6,573.7 crore in Q1 FY26 from ₹6,207.5 crore a year earlier on the back of new drug launches in the US

Zydus Lifesciences up 2% after USFDA nods Diltiazem Hydrochloride tablets

Zydus Lifesciences share price rose 2 per cent, logging an intra-day high at ₹955 per share on BSE after USFDA gave its approval for Diltiazem Hydrochloride Tablets.